Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Roflumilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 18/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 8/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 8/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roflumilast SCHEMBL19158 | 1.00 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL18095182 | 1.00 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29033058 | 0.99 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29039838 | 0.99 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL28150332 | 0.99 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL20677818 | 0.98 | PDE4B (0.96) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29191360 | 0.98 | PDE4B (0.96) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL2885525 | 0.96 | PDE4B (0.93) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL30084825 | 0.96 | PDE4B (0.93) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL2887750 | 0.96 | PDE4B (0.92) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130897-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4683942-A1 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ADMINISTERING AN IL-4R ANTAGONIST | Sanofi Biotechnology (FR) | 2026-01-28 | — | — | EP | claimed |
| EP-4197318-B1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-11-19 | — | — | EP | claimed |
| US-12390453-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | claimed |
| EP-4493190-A1 | SELF-PRESERVING TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING DIETHYLENE GLYCOL MONOETHYL ETHER | Arcutis Biotherapeutics, Inc. (US) | 2025-01-22 | — | — | EP | claimed |
| US-20240374576-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-11-14 | — | — | US | claimed |
| WO-2024197119-A1 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ADMINISTERING AN IL-4R ANTAGONIST | SANOFI BIOTECHNOLOGY (FR) | 2024-09-26 | — | — | WO | claimed |
| US-12042487-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | claimed |
| US-11957656-B2 | Methods of treating Prader-Willi syndrome | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-16 | — | — | US | claimed |
| EP-4175619-B1 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | ASTRAZENECA PHARMACEUTICALS LP (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4329849-A1 | INHALER | 3D Engineering Design Limited (GB) | 2024-03-06 | — | — | EP | claimed |
| US-20240024300-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | claimed |
| US-20240000760-A1 | Roflumilast Formulations with an Improved Pharmacokinetic Profile | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-01-04 | — | — | US | claimed |
| WO-2023196234-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310380-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| WO-2023177416-A1 | SELF-PRESERVING TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING DIETHYLENE GLYCOL MONOETHYL ETHER | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2023133575-A2 | METHODS AND SYSTEMS FOR TREATING CHRONIC ITCH CONDITIONS USING DIGITAL THERAPEUTICS IN COMBINATION WITH OTHER THERAPIES | Mahana Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | claimed |
| EP-4093205-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | KNOW Bio, LLC (US) | 2022-11-30 | — | — | EP | claimed |
| WO-2022229665-A1 | INHALER | 3D Engineering Design Limited (GB) | 2022-11-03 | — | — | WO | claimed |
| WO-2022169615-A1 | ROFLUMILAST FORMULATIONS WITH AN IMPROVED PHARMACOKINETIC PROFILE | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000760-A1 | Roflumilast Formulations with an Improved Pharmacokinetic Profile | PDE12, PDE4A, PDE4B | PDE4B 3/4885PDE4D 5/4885PDE4A 2/4885 |
| US-12042487-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | PDE12, PDE4A, SMPD4 | PDE4B 4/4885PDE4D 7/4885PDE4A 2/4885 |
| US-20240024300-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, PDE4A, SMPD4 | PDE4B 4/4885PDE4D 7/4885PDE4A 2/4885 |
| US-12390453-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | PDE12, PDE4A, SMPD4 | PDE4B 4/4885PDE4D 7/4885PDE4A 2/4885 |
| US-20240374576-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, PDE4A, SMPD4 | PDE4B 4/4885PDE4D 7/4885PDE4A 2/4885 |
| US-20260130897-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, SMPD4, PDE4A | PDE4B 4/4885PDE4D 6/4885PDE4A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.